글로벌 자가 주사 시장 규모, 점유율 및 추세 분석 보고서 – 2031년까지의 산업 추세 및 예측

보고서 사용자 지정 보고서 사용자 지정 지금 구매 지금 구매 무료 샘플 보고서 무료 샘플 보고서
집 Healthcare Global Self Injections Market
TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

글로벌 자가 주사 시장 규모, 점유율 및 추세 분석 보고서 – 2031년까지의 산업 추세 및 예측

  • Healthcare
  • Published Report
  • Sep 2024
  • Global
  • 350 Pages
  • 테이블 수: 847
  • 그림 수: 51
지금 구매 지금 구매

Global Self Injections Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Diagram 예측 기간
 2024 –2031
Diagram 시장 규모(기준 연도)
 USD 46.18 Billion
Diagram 시장 규모(예측 연도)
 USD 97.36 Billion
Diagram 연평균 성장률
 %
Diagram 주요 시장 플레이어
  • Bristol-Myers Squibb Company (U.S)
  • Pfizer Inc. (U.S)
  • Mylan N.V. (U.S)
  • Merck & Co.
  • Inc. (U.S)

>글로벌 자가 주사 시장 세분화, 제품 유형(자가 주사 기기 및 자가 주사 제형), 투여 형태(단일 투여 및 다중 투여), 투여 경로(피하, 근육 내 및 기타), 응용 분야( 자가 면역 질환통증 관리 , 응급 약물, 종양학, 호르몬 장애 및 기타), 연령대(성인, 노인 및 소아), 성별(남성 및 여성), 유통 채널(직접 입찰, 병원 약국, 온라인 약국 및 기타) - 업계 동향 및 2031년까지의 예측.

자가 주사 시장

자가 주사 시장 분석

글로벌 자가 주사 시장은 만성 질환 의 유병률 증가 , 자가 주사의 기술 발전, 환자 자율성 증가, 모바일 건강 애플리케이션의 증가에 의해 주도되고 있습니다. 이 시장은 주요 업체의 존재, 지속적인 연구 개발, 전략적 협업이 특징입니다. 시장 확장은 또한 유리한 규제 환경과 증가하는 의료 지출에 의해 뒷받침됩니다. 자가 주사기 , 펜 주사기 , 착용형 주사기를 포함한 자가 주사 장치는 편의성, 사용 용이성, 개인이 집에서 자신의 약을 투여할 수 있어 환자의 준수를 향상시키고 빈번한 의료 방문의 필요성을 줄여 환자 준수를 향상시킬 수 있는 능력으로 인해 점점 더 인기를 얻고 있습니다. 환자의 준수를 추적하고 모니터링하는 연결된 장치와 같은 기술 혁신은 시장 성장을 더욱 촉진하고 있습니다.

자가 주사 시장자가 주사 시장

자가 주사 시장 규모

글로벌 자가 주사 시장 규모는 2023년에 461억 8천만 달러로 평가되었으며, 2031년까지 973억 6천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 10.0%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

자가 주사 시장 동향

“사용자 친화적이고 일회용 기기에 초점을 맞춰 상승”

글로벌 자가 주사 시장의 주요 추세는 사용자 친화적이고 일회용인 기기에 대한 수요가 증가하고 있다는 것입니다. 당뇨병, 류마티스 관절염, 다발성 경화증과 같은 만성 질환을 관리하는 환자가 늘어나면서 사용하기 쉬운 자가 투여 시스템에 대한 필요성이 커지고 있습니다. 자동 주사기 및 사전 충전 주사기와 같은 자가 주사 기기는 주사 과정을 단순화하여 환자의 준수를 개선하도록 설계되었습니다. 이러한 추세는 환자가 치료 요법을 더 많이 통제하도록 권장되어 의료 시설을 자주 방문할 필요성이 줄어드는 가정 기반 치료로의 광범위한 전환과 일치합니다.

또한, 기술적 발전이 이 시장에서 혁신을 주도하고 있습니다. 제조업체는 복용량 추적 및 실시간 피드백과 같은 스마트 기능을 자가 주사 장치에 통합하고 있습니다. 이러한 기능은 특히 빈번한 주사가 필요한 환자에게 유익합니다. 정밀도를 높이고 과소 또는 과다 복용 위험을 줄이기 때문입니다. 향상된 안전성, 편의성 및 디지털 통합의 조합은 특히 환자 인구가 증가하고 의료 인식이 높아지는 지역에서 자가 주사 장치의 채택을 전 세계적으로 가속화할 가능성이 높습니다.

보고서 범위 및 자가 주사 시장 세분화       

속성

자가 주사 주요 시장 통찰력

다루는 세그먼트
  • 제품 유형별 : 자가 주사 장치 및 자가 주사 제형
  • 투여 형태별 : 단일 투여 및 다중 투여
  • 투여 경로 : 피하, 근육내 및 기타
  • 응용 분야 : 자가면역 질환, 통증 관리, 응급 약물, 종양학, 호르몬 장애 및 기타
  • 연령대별 : 성인, 노인 및 소아
  • 성별별 : 남성 및 여성
  • 유통채널별 : 직접입찰, 병원약국, 온라인약국 등

적용 국가

미국, 캐나다, 멕시코, 영국, 독일, 프랑스, ​​스페인, 이탈리아, 벨기에, 러시아, 스위스, 네덜란드, 터키, 덴마크, 스웨덴, 노르웨이, 폴란드, 핀란드, 유럽의 나머지 지역, 중국, 호주, 일본, 인도, 싱가포르, 한국, 말레이시아, 태국, 인도네시아, 필리핀, 뉴질랜드, 베트남, 대만, 아시아 태평양의 나머지 지역, 브라질, 아르헨티나, 그리고 남미의 나머지 지역, 남아프리카, 이집트, 사우디 아라비아, UAE, 이스라엘, 쿠웨이트, 오만, 카타르, 바레인, 그리고 중동과 아프리카의 나머지 지역

주요 시장 참여자

Bayer AG (Germany), UCB Pharma (Belgium), Ipsen Biopharmaceuticals, Inc. (France), Teva Pharmaceuticals Industries Ltd (Israel), Recipharm AB (Sweden), SCHOTT Pharma (Germany), Lilly (U.S.), AstraZeneca (U.K.), Takeda Pharmaceuticals Company Limited (Japan), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Sanofi (France), AbbVie (U.S.), Biogen (U.S.), YPSOMED (Switzerland), Bausch Health Companies Inc. (Canada), Merck & Co. (U.S.), Amgen Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Penjet (U.S.), PharmaJet (U.S.), Societe Industrielle de Sonceboz SA (Switzerland), Terumo Corporation (Japan), Haselmeier (Germany), Owen Mumford (U.K.), Midas Pharma GmbH (Germany), BD (U.S.), Phillips-Medisize (U.S.), West Pharmaceutical Services (U.S.), E3D Elcam Drug Delivery Devices (Israel), Gerresheimer AG (Germany), Enable Injections (U.S.), Dali Medical Devices (Israel), Credence Medsystems, Inc. (U.S.), Nemera (France), Oval Medical Technologies Ltd. (SMC Limited) (U.K.), SHL Medical AG (Switzerland), Novo Nordisk A/S (Denmark), AptarGroup, Inc. (U.S.), Boehringer Ingelheim International GmbH (Germany), F. Hoffmann-La Roche Ltd (Switzerland), and GSK plc (U.K.) among others

Market Opportunities

  • Growing Demand for Biologics and Personalized Medicine
  • Government Initiatives to Self-Injections

Value Added Data Infosets

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Self-Injections Market Definition

The global self-injections market refers to the industry that focuses on the development, manufacturing, and distribution of devices and technologies enabling patients to self-administer medications without requiring the direct involvement of healthcare professionals. These devices, such as auto-injectors, prefilled syringes, pen injectors, and wearable injectors, are designed to deliver a wide range of treatments, including biologics, insulin, hormones, and therapies for chronic conditions like diabetes, rheumatoid arthritis, and multiple sclerosis. The market is driven by several factors, including the increasing prevalence of chronic diseases, a growing preference for home-based healthcare, the rising demand for biologics and personalized medicine, and advancements in drug delivery technology that emphasize user-friendly designs, safety, and reliability.                  

Self-Injections Market Dynamics

Drivers  

  • Rising Prevalence of Chronic Disease    

The growing prevalence of chronic diseases, including diabetes, arthritis, and multiple sclerosis, is a key driver for the self-injection market. Patients with these conditions frequently require ongoing medication, making self-injection devices both convenient and essential. As the global population ages, the demand for effective at-home treatment options continues to rise. Self-injection systems empower patients to manage their conditions independently, significantly reducing the need for hospital visits. This shift not only improves patient adherence and quality of life but also eases the burden on healthcare systems, driving further market growth. The increasing focus on personalized healthcare solutions supports the expansion of self-injection technologies, catering to the needs of a diverse patient population seeking greater autonomy in their treatment regimens.

For instance,
In January 2024, according to the article published in NCBI, Chronic diseases such as diabetes and heart disease are leading causes of global morbidity and mortality, with costs projected to reach USD 47 trillion by 2030.So, prevalence of chronic diseases like diabetes act as driver for the market.              

  • Technological Advancement in Self Injections             

Recent innovations in medical technology have resulted in the creation of advanced self-injection devices that prioritize user-friendliness and efficiency. Features like auto-injectors, pre-filled syringes, and smart devices integrated with mobile applications significantly enhance the user experience by offering real-time feedback and reminders. These improvements increase the accuracy of medication delivery and reduce the likelihood of errors, making self-injection more attractive to patients. As healthcare increasingly shifts toward a patient-centric model, the demand for these technologically advanced solutions is expected to rise. This trend is likely to propel the self-injection market forward, catering to patients seeking greater autonomy and improved management of their health conditions. Such innovations not only enhance patient satisfaction but also contribute to better health outcomes overall.

For instance,
In October 2023, according to the article published in Frederick Furness Publishing, It explores innovative solutions to address the challenges of injecting high-viscosity medications, which are often difficult to deliver with traditional devices. By highlighting technological advancements, it discusses how improved syringe designs and automated delivery systems enhance the ease and effectiveness of self-injection, which act as driver in the market growth.

자가 주사 시장

Opportunities

  • Government Initiatives to Self-Injections

Government initiatives promoting self-injection therapies present significant opportunities in the global self-injections market. Many governments are focused on enhancing patient-centric healthcare and reducing the strain on overburdened healthcare systems. To achieve this, several national healthcare bodies are actively encouraging self-administration practices by offering educational programs, subsidies, and regulatory support for self-injection devices. These initiatives aim to empower patients to manage chronic diseases at home, improving access to treatment in rural or underserved areas and reducing hospital visits. Also, favorable reimbursement policies for self-injection devices and medications further incentivize both patients and manufacturers. Government support in the form of funding for research and development of innovative self-injection technologies, alongside the streamlining of regulatory approval processes, accelerates the availability of safer, more user-friendly devices. This growing governmental backing facilitates market expansion by creating a conducive environment for the adoption of self-injections, ultimately fostering increased growth potential for manufacturers and healthcare providers alike.    

For instance,

In October 2023, according to the information published by UNFPA (United Nations Population Fund), UNFPA is a United Nations agency that works to improve reproductive health and maternal health worldwide promotes the incorporation of Injection Depot MedroxyProgesterone Acetate - Subcutaneous (DMPA-SC) as a self-injection contraceptive option into India’s national Family Planning Programme represents a promising and well-timed timely opportunity and plays a crucial role in addressing the unmet need of contraception among women particularly those from vulnerable communities who encounter numerous barriers to accessing contraceptives. Self-injection plays a vital role in enhancing and diversifying choices, promoting self-care practices.

  • Increased Research and Development for Self-injection

Increased research and development (R&D) in self-injection technologies serve as a key opportunity in the global self-injections market by driving innovation that meets the evolving needs of patients and healthcare systems. Emerging advancements are focused on creating more intuitive, user-friendly devices that improve safety, convenience, and patient compliance. These innovations include the development of smart injectors with digital health capabilities, needle-free systems, and auto-injectors designed for easier handling and reduced pain. Also, R&D is expanding the range of injectable drugs that can be self-administered, particularly in areas such as biologics, insulin, and cancer therapies, which increases the market potential. The integration of connectivity features, enabling patients to share real-time data with healthcare providers, further enhances the personalized treatment experience and aligns with the global shift toward patient-centered care. As pharmaceutical companies and device manufacturers invest in cutting-edge technologies, these advancements not only broaden the application of self-injection devices but also drive adoption and open new growth avenues in the global market.  

For instance,

In May 2023, according to the article published in Springer, the SMARTCLIC/CLICWISE injection device, an electromechanical auto injector developed by PHC Corporation (Tokyo, Japan), was recently introduced for subcutaneous administration of biologic therapies. The research and development program for this device was strategically designed to create a user-friendly, multi-use auto injector specifically for single-patient applications. This innovation aims to offer patients and caregivers an advanced administration option, expanding beyond traditional self-injection methods such as vials with empty syringes, prefilled pens or syringes, and earlier auto injector models.

Restraints/Challenges

  • High Cost of Self Injectors    

The high cost of self-injectors acts as a significant restraint in the global self-injections market by limiting accessibility for many patients and healthcare providers. Despite their convenience and potential to reduce hospital visits, the premium pricing of advanced self-injection devices, such as auto-injectors and wearable systems, makes them unaffordable for a large portion of the population, particularly in low-income regions or for those without comprehensive insurance coverage. This financial barrier often leads to reduced patient adherence to prescribed treatments, as many cannot afford the necessary devices for long-term use. Also, healthcare systems may be hesitant to invest in these high-cost solutions, which further slows their adoption and market penetration. Addressing the issue of affordability is therefore essential to broadening the reach and effectiveness of self-injection technologies.       

For instance,

In July 2022, according to the article published in NCBI, for patients at risk of anaphylaxis, the high cost of epinephrine auto-injectors poses a significant barrier to accessing this life-saving treatment. Between 2014 and 2020, the list price of the leading auto-injector, the branded EpiPen, tripled, while annual out-of-pocket expenses for privately insured individuals doubled. In 2019, median out-of-pocket costs per two-pack were USD 736 for Auvi-Q, USD 63 for branded EpiPen, and just USD 10 for non-branded alternatives. Overall, in 2019, the annual out-of-pocket spending on epinephrine auto-injectors was USD 200 for 96,073 patients (50.8%), while it exceeded USD 500 for 11,863 patients (9.5%). This high cost of self-injection significantly impacts patient access and adherence to necessary treatment.  

  • Regulatory Hurdles and Need for Proper Training for Self-Injection Devices 

Regulatory hurdles and the need for proper training act as significant restraints in the global self-injections market, slowing down both product availability and adoption. Stringent regulations and varying approval processes across different countries can delay the launch of innovative self-injection devices, as manufacturers must navigate complex and time-consuming approval pathways. This not only hampers innovation but also restricts the global reach of these products. Also, even after regulatory approval, the need for proper training becomes a barrier. Self-injection devices require patients and healthcare providers to be well-versed in their use to ensure safety and efficacy. Without comprehensive training programs, patients may misuse the devices, leading to improper dosing, health risks, and reduced treatment adherence. Healthcare providers must also invest time and resources into educating patients, which can be a burden in already stretched healthcare systems. The lack of widespread training infrastructure, especially in developing regions, further limits the potential growth of the self-injection market. Therefore, both regulatory complexities and the demand for patient education are key factors holding back the market's expansion.

For instance,

In December 2022, according to the article published in NCBI, the design of pen injectors is subject to strict regulations from various government bodies, including the US Food and Drug Administration, and must adhere to industry standards such as ISO 11608 and ISO 60601. These regulations require extensive testing to ensure that the delivered dose matches the set dose, especially for multidose pen injectors. In addition, manufacturers must conduct biocompatibility testing for all components of the device and the formulation, assessing potential leachables or extractables and their impact on the insulin formulation. Other regulatory considerations include shelf-life stability, the effects of environmental conditions on device performance, sterilization, usability testing, and visual inspection capabilities. For smart pens with electronic components, testing must also account for performance under various environmental conditions, such as heat and humidity, to ensure safety and accuracy.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Self-Injections Market Scope

The market is segmented on the basis of product type, dosage form, route of administration, application, age group, gender and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

  • Self-Injection Devices
    •  Auto Injectors
      • Disposable
      • Reusable
    •  Pen Injectors
      • Disposable
      • Reusable
    •  Wearable Injectors
      • Disposable
      • Reusable
    •  Needle-Free Injectors
      • Disposable
      • Reusable
  •  Self-Injection Formulation     

Dosage Form

  • Single Dose
  • Multi-Dose

Route of Administration

  • Subcutaneous
  • Intra muscular
  • Others

Application

  • Autoimmune Diseases
  • Pain Management
  • Emergency Drugs
    • Respiratory Therapy
    •  Migraine
    •  Anaphylactic Shock
    •  Others
  •  Oncology
  •  Hormonal Disorders
    • Osteoporosis
    •  Hypogonadism
    •  Adrenal Insufficiency
    •  Others
  •  Others

Age Group

  • Adult
  • Geriatric
  • Pediatric

Gender

  • Male
  • Female

Distribution Channel

  • Direct Tender
  • Hospital Pharmacy
  • Online Pharmacy
  • Others

자가 주사 시장

Self-Injections Market Regional Analysis

The market is analyzed and market size insights and trends are provided by country, product type, dosage form, route of administration, application, age group, gender and distribution channel as referenced above.

The countries covered in the market are U.S., Canada, and Mexico, U.K., Germany, France, Spain, Italy, Belgium, Russia, Switzerland, Netherlands, Turkey, Rest of Europe, China, Australia, Japan, India, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, and rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and rest of Middle East and Africa.

North America is expected to dominate the market due to its advanced healthcare infrastructure, high prevalence of chronic diseases, and strong adoption of innovative medical technologies.

Asia-Pacific is expected to be the fastest growing due to its expanding healthcare infrastructure, increasing prevalence of chronic diseases, and rising patient awareness of self-care solutions.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

자가 주사 시장

Self-Injections Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Self-Injections Market Leaders Operating in the Market Are:

  • Bayer AG (Germany)
  • UCB Pharma (Belgium)
  • Ipsen Biopharmaceuticals, Inc. (France)
  • Teva Pharmaceuticals Industries Ltd (Israel)
  • Recipharm AB (Sweden)
  • SCHOTT Pharma (Germany)
  • Lilly (U.S.)
  • AstraZeneca (U.K.)
  • Takeda Pharmaceuticals Company Limited (Japan)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (U.S.)
  • Sanofi (France)
  • AbbVie (U.S.)
  • Biogen (U.S.)
  • YPSOMED (Switzerland)
  • Bausch Health Companies Inc. (Canada)
  • Merck & Co. (U.S.)
  • Amgen Inc. (U.S.)
  • Johnson & Johnson Services, Inc. (U.S.)
  • Penjet (U.S.)
  • PharmaJet (U.S.)
  • Societe Industrielle de Sonceboz SA (Switzerland)
  • Terumo Corporation (Japan)
  • Haselmeier (Germany)
  • Owen Mumford (U.K.)
  • Midas Pharma GmbH (Germany)
  • BD (U.S.)
  • Phillips-Medisize (U.S.)
  • West Pharmaceutical Services (U.S.)
  • E3D Elcam Drug Delivery Devices (Israel)
  • Gerresheimer AG (Germany)
  • Enable Injections (U.S.)
  • Dali Medical Devices (Israel)
  • Credence Medsystems, Inc. (U.S.)
  • Nemera (France)
  • Oval Medical Technologies Ltd. (SMC Limited) (U.K.)
  • SHL Medical AG(스위스)
  • Novo Nordisk A/S(덴마크)
  • AptarGroup, Inc. (미국)
  • 베링거인겔하임인터내셔널(독일)
  • F. 호프만-라 로슈 유한회사(스위스)
  • GSK plc (영국)

자가 주사 시장의 최신 동향

  • 2024년 9월, Evotec 주가는 세포 치료를 중심으로 Novo Nordisk와 기술 개발 파트너십을 발표한 후 6% 상승했습니다. 이 협력에는 독일과 이탈리아의 개발 활동에 대한 자금 지원, 선불금, 잠재적인 이정표 성과 및 로열티 인센티브가 포함됩니다. Evotec의 최고 과학 책임자인 Cord Dohrmann 박사는 이 파트너십을 통해 혁신적인 줄기 세포 기반 치료법을 만드는 것에 대해 낙관적인 입장을 표명했습니다.
  • 2024년 9월, Tremfya(guselkumab)는 플라크 건선 및 건선성 관절염에 대한 승인 외에도 중등도에서 중증의 활성 궤양성 대장염이 있는 성인을 대상으로 FDA 승인을 받았습니다. 이 질환에 대한 최초의 이중 작용 인터루킨-23 억제제로, QUASAR 연구에서 상당한 완화율을 보였습니다. 200mg 정맥 유도 용량으로 투여한 후 8주마다 100mg 또는 4주마다 200mg의 피하 유지 용량을 투여합니다. 이 승인은 염증성 장 질환에 대한 치료법을 발전시키려는 Johnson & Johnson의 의지를 강조합니다.
  • 2024년 7월, Biogen은 Human Immunology Biosciences(HI-Bio)를 인수하여 유망한 치료 후보인 펠자르타맙으로 면역학 파이프라인을 강화했습니다. 이 인수를 통해 펠자르타맙은 다양한 적응증에 대한 3상 시험으로 진행될 것입니다. IgA 신병증 및 항체 매개 거부에 대한 2상 연구에서 긍정적인 중간 결과가 보고되었습니다.
  • 2024년 7월, Biogen은 Human Immunology Biosciences(HI-Bio)를 인수하여 유망한 치료 후보인 펠자르타맙으로 면역학 파이프라인을 강화했습니다. 이 인수를 통해 펠자르타맙은 다양한 적응증에 대한 3상 시험으로 진행될 것입니다. IgA 신병증 및 항체 매개 거부에 대한 2상 연구에서 긍정적인 중간 결과가 보고되었습니다.
  • 2024년 7월, AstraZeneca는 최대 10억 5천만 달러에 Amolyt Pharma를 성공적으로 인수하여 Alexion Rare Disease 파이프라인을 강화했습니다. 여기에는 저갑상선기능저하증에 대한 3상 펩타이드 에네보파라티드가 포함되어 AstraZeneca의 희귀 내분비 질환 및 칼슘 조절 치료에 대한 집중을 확대합니다.
  • 2024년 6월, Aptar Digital Health는 SHL Medical과 협력하여 SaMD 플랫폼을 통합하여 연결된 장치 기술을 개선했습니다. 이 협업은 주사 요법의 자가 투여 중 환자 경험을 개선하고 환자의 더 나은 준수와 질병 관리를 지원하는 것을 목표로 했습니다.

SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

Sample Image Click on image to enlarge
  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL SELF-INJECTIONS MARKET

1.4 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 THERAPEUTICS LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET APPLICATION COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 CUSTOMIZATIONS

5 GLOBAL SELF-INJECTIONS MARKET: REGULATIONS

5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION

5.1.1 AUSTRALIA

5.1.2 CHINA

5.1.3 INDIA

5.2 REGULATORY SUBMISSIONS

5.2.1 PRE-SUBMISSION ACTIVITIES

5.2.2 DEVELOPMENT OF TECHNICAL DOCUMENTATION

5.3 CLINICAL EVALUATION

5.4 REGULATORY SUBMISSION PREPARATION

5.5 SUBMISSION TO REGULATORY AUTHORITY

5.6 REVIEW AND EVALUATION BY REGULATORY AUTHORITY

5.7 APPROVAL AND MARKET AUTHORIZATION

5.8 POST-MARKET SURVEILLANCE

5.9 RENEWAL AND COMPLIANCE

5.1 ASEAN MEDICAL DEVICE DIRECTIVE (AMDD)

5.11 ADOPTION OF GLOBAL STANDARDS (ISO AND IEC)

5.12 COLLABORATION VIA APEC REGULATORY HARMONIZATION STEERING COMMITTEE

5.13 CLINICAL DATA HARMONIZATION

5.14 COMMON TECHNICAL DOCUMENT (CTD) FORMAT

5.15 POST-MARKET SURVEILLANCE AND REPORTING HARMONIZATION

5.16 MUTUAL RECOGNITION AGREEMENTS (MRAS)

5.17 TRAINING AND CAPACITY BUILDING INITIATIVES

5.18 NORTH AMERICA REGULATORY SCENARIO

5.19 MEDICAL DEVICE CLASSIFICATION

5.2 REGULATORY SUBMISSIONS

5.21 EUROPE REGULATORY SCENARIO

5.22 REGULATORY SUBMISSIONS

5.23 MIDDLE EAST AND AFRICA REGULATORY SCENARIO

5.24 SOUTH AMERICA REGULATORY SCENARIO

5.25 INTERNATIONAL HARMONIZATION

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING PREVALENCE OF CHRONIC DISEASE

6.1.2 TECHNOLOGICAL ADVANCEMENT IN SELF INJECTIONS

6.1.3 INCREASE IN PATIENT AUTONOMY

6.1.4 RISE IN MOBILE HEALTH APPLICATIONS

6.2 RESTRAINTS

6.2.1 HIGH COST OF SELF INJECTORS

6.2.2 REGULATORY HURDLES AND NEED FOR PROPER TRAINING FOR SELF-INJECTION DEVICES

6.3 OPPORTUNITIES

6.3.1 GOVERNMENT INITIATIVES TO SELF-INJECTIONS

6.3.2 INCREASED RESEARCH AND DEVELOPMENT FOR SELF-INJECTION

6.3.3 GROWING DEMAND FOR BIOLOGICS AND PERSONALIZED MEDICINE

6.4 CHALLENGES

6.4.1 PATIENT RELUCTANCE TOWARDS NEEDLES

6.4.2 ENVIRONMENTAL CONCERNS WITH SELF-INJECTIONS

7 GLOBAL SELF-INJECTIONS MARKET, BY PRODUCT TYPE

7.1 OVERVIEW

7.2 SELF-INJECTION DEVICES

7.3 SELF-INJECTION FORMULATION

8 GLOBAL SELF-INJECTIONS MARKET, BY DOSAGE FORM

8.1 OVERVIEW

8.2 SINGLE DOSE

8.3 MULTI-DOSE

9 GLOBAL SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION

9.1 OVERVIEW

9.2 SUBCUTANEOUS

9.3 INTRA MUSCULAR

9.4 OTHERS

10 GLOBAL SELF-INJECTIONS MARKET, BY APPLICATION

10.1 OVERVIEW

10.2 AUTOIMMUNE DISEASES

10.3 PAIN MANAGEMENT

10.4 EMERGENCY DRUGS

10.5 ONCOLOGY

10.6 HORMONAL DISORDERS

10.7 OTHERS

11 GLOBAL SELF-INJECTIONS MARKET, BY AGE GROUP

11.1 OVERVIEW

11.2 ADULT

11.3 GERIATRIC

11.4 PEDIATRIC

12 GLOBAL SELF-INJECTIONS MARKET, BY GENDER

12.1 OVERVIEW

12.2 MALE

12.3 FEMALE

13 GLOBAL SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL

13.1 OVERVIEW

13.2 DIRECT TENDER

13.3 HOSPITAL PHARMACY

13.4 ONLINE PHARMACY

13.5 OTHERS

14 GLOBAL SELF-INJECTIONS MARKET, BY REGION

14.1 OVERVIEW

14.2 GLOBAL

14.3 NORTH AMERICA

14.4 EUROPE

14.5 ASIA-PACIFIC

14.6 SOUTH AMERICA

14.7 MIDDLE EAST AND AFRICA

15 GLOBAL SELF-INJECTIONS MARKET: COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: GLOBAL

15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

15.3 COMPANY SHARE ANALYSIS: EUROPE

15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

16 SWOT ANALYSIS

17 COMPANY PROFILES

17.1 NOVO NORDISK

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE

17.1.3 COMPANY SHARE ANALYSIS

17.1.4 PRODUCT PORTFOLIO

17.1.5 RECENT DEVELOPMENT

17.2 JOHNSON & JOHNSON SERVICES, INC.

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 COMPANY SHARE ANALYSIS

17.2.4 PRODUCT PORTFOLIO

17.2.5 RECENT DEVELOPMENT

17.3 BIOGEN

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 PRODUCT PORTFOLIO

17.3.4 RECENT DEVELOPMENT

17.4 AMGEN INC.

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 COMPANY SHARE ANALYSIS

17.4.4 PRODUCT PORTFOLIO

17.4.5 RECENT DEVELOPMENT

17.5 SANOFI

17.5.1 COMPANY SNAPSHOT

17.5.2 REVENUE ANALYSIS

17.5.3 COMPANY SHARE ANALYSIS

17.5.4 PRODUCT PORTFOLIO

17.5.5 RECENT DEVELOPMENT

17.6 ABBVIE INC.

17.6.1 COMPANY SNAPSHOT

17.6.2 REVENUE ANALYSIS

17.6.3 COMPANY SHARE ANALYSIS

17.6.4 PRODUCT PORTFOLIO

17.6.5 RECENT DEVELOPMENT

17.7 YPSOMED

17.7.1 COMPANY SNAPSHOT

17.7.2 REVENUE ANALYSIS

17.7.3 PRODUCT PORTFOLIO

17.7.4 RECENT DEVELOPMENT

17.8 BD

17.8.1 COMPANY SNAPSHOT

17.8.2 REVENUE ANALYSIS

17.8.3 PRODUCT PORTFOLIO

17.8.4 RECENT DEVELOPMENT

17.9 ASTRAZENECA

17.9.1 COMPANY SNAPSHOT

17.9.2 REVENUE ANALYSIS

17.9.3 PRODUCT PORTFOLIO

17.9.4 RECENT DEVELOPMENTS

17.1 APTARGROUP, INC.

17.10.1 COMPANY SNAPSHOT

17.10.2 REVENUE ANALYSIS

17.10.3 PRODUCT PORTFOLIO

17.10.4 RECENT DEVELOPMENTS

17.11 BAYER

17.11.1 COMPANY SNAPSHOT

17.11.2 REVENUE

17.11.3 PRODUCT PORTFOLIO

17.11.4 RECENT DEVELOPMENT

17.12 BAUSCH HEALTH COMPANIES INC.

17.12.1 COMPANY SNAPSHOT

17.12.2 REVENUE ANALYSIS

17.12.3 PRODUCT PORTFOLIO

17.13 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

17.13.1 COMPANY SNAPSHOT

17.13.2 REVENUE ANALYSIS

17.13.3 PRODUCT PORTFOLIO

17.13.4 RECENT DEVELOPMENTS

17.14 CREDENCE MEDSYSTEMS, INC.

17.14.1 COMPANY SNAPSHOT

17.14.2 PRODUCT PORTFOLIO

17.14.3 RECENT DEVELOPMENT

17.15 DALI MEDICAL DEVICES

17.15.1 COMPANY SN.APSHOT

17.15.2 PRODUCT PORTFOLIO

17.15.3 RECENT DEVELOPMENT

17.16 ENABLE INJECTIONS

17.16.1 COMPANY SNAPSHOT

17.16.2 PRODUCT PORTFOLIO

17.16.3 RECENT DEVELOPMENTS

17.17 E3D ELCAM DRUG DELIVERY DEVICES

17.17.1 COMPANY SNAPSHOT

17.17.2 PRODUCT PORTFOLIO

17.17.3 RECENT DEVELOPMENT

17.18 F. HOFFMANN-LA ROCHE LTD

17.18.1 COMPANY SNAPSHOT

17.18.2 REVENUE ANALYSIS

17.18.3 PRODUCT PORTFOLIO

17.18.4 RECENT DEVELOPMENT

17.19 GSK PLC

17.19.1 COMPANY SNAPSHOT

17.19.2 REVENUE ANALYSIS

17.19.3 PRODUCT PORTFOLIO

17.19.4 RECENT DEVELOPMENTS

17.2 GERRESHEIMER AG

17.20.1 COMPANY SNAPSHOT

17.20.2 REVENUE ANALYSIS

17.20.3 PRODUCT PORTFOLIO

17.20.4 RECENT DEVELOPMENTS

17.21 HASELMEIER

17.21.1 COMPANY SNAPSHOT

17.21.2 PRODUCT PORTFOLIO

17.21.3 RECENT DEVELOPMENT

17.22 IPSEN BIOPHARMACEUTICALS, INC.

17.22.1 COMPANY SNAPSHOT

17.22.2 REVENUE ANALYSIS

17.22.3 PRODUCT PORTFOLIO

17.22.4 RECENT DEVELOPMENT

17.23 LILLY

17.23.1 COMPANY SNAPSHOT

17.23.2 REVENUE ANALYSIS

17.23.3 PRODUCT PORTFOLIO

17.23.4 RECENT DEVELOPMENT

17.24 MIDAS PHARMA GMBH

17.24.1 COMPANY SNAPSHOT

17.24.2 PRODUCT PORTFOLIO

17.24.3 RECENT DEVELOPMENT

17.25 MERCK & CO., INC.,

17.25.1 COMPANY SNAPSHOT

17.25.2 REVENUE ANALYSIS

17.25.3 PRODUCT PORTFOLIO

17.25.4 RECENT DEVELOPMENT

17.26 NOVARTIS AG

17.26.1 COMPANY SNAPSHOT

17.26.2 REVENUE ANALYSIS

17.26.3 PRODUCT PORTFOLIO

17.26.4 RECENT DEVELOPMENTS

17.27 NEMERA

17.27.1 COMPANY SNAPSHOT

17.27.2 PRODUCT PORTFOLIO

17.27.3 RECENT DEVELOPMENT

17.28 OVAL MEDICAL TECHNOLOGIES LTD. (SMC LIMITED)

17.28.1 COMPANY SNAPSHOT

17.28.2 PRODUCT PORTFOLIO

17.28.3 RECENT DEVELOPMENT

17.29 OWEN MUMFORD

17.29.1 COMPANY SNAPSHOT

17.29.2 PRODUCT PORTFOLIO

17.29.3 RECENT DEVELOPMENT

17.3 PFIZER INC.

17.30.1 COMPANY SNAPSHOT

17.30.2 REVENUE ANALYSIS

17.30.3 PRODUCT PORTFOLIO

17.30.4 RECENT DEVELOPMENT

17.30.5 RECENT DEVELOPMENT

17.31 PHILIP MEDSIZE

17.31.1 COMPANY SNAPSHOT

17.31.2 PRODUCT PORTFOLIO

17.31.3 RECENT DEVELOPMENTS

17.32 PHARMAJET.

17.32.1 COMPANY SNAPSHOT

17.32.2 PRODUCT PORTFOLIO

17.32.3 RECENT DEVELOPMENT

17.33 PENJET

17.33.1 COMPANY SNAPSHOT

17.33.2 1.1.4 PRODUCT PORTFOLIO

17.33.3 RECENT DEVELOPMENT

17.34 RECIPHARM AB

17.34.1 COMPANY SNAPSHOT

17.34.2 PRODUCT PORTFOLIO

17.34.3 RECENT DEVELOPMENTS

17.35 SCHOTT PHARMA

17.35.1 COMPANY SNAPSHOT

17.35.2 PRODUCT PORTFOLIO

17.35.3 RECENT DEVELOPMENTS

17.36 SHL MEDICAL AG

17.36.1 COMPANY SNAPSHOT

17.36.2 PRODUCT PORTFOLIO

17.36.3 RECENT DEVELOPMENT

17.37 SOCIÉTÉ INDUSTRIELLE DE SONCEBOZ SA

17.37.1 COMPANY SNAPSHOT

17.37.2 PRODUCT PORTFOLIO

17.37.3 RECENT DEVELOPMENT

17.38 TERUMO CORPORATION

17.38.1 COMPANY SNAPSHOT

17.38.2 REVENUE ANALYSIS

17.38.3 PRODUCT PORTFOLIO

17.38.4 RECENT DEVELOPMENT

17.39 TAKEDA PHARMACEUTICAL COMPANY LIMITED

17.39.1 COMPANY SNAPSHOT

17.39.2 REVENUE ANALYSIS

17.39.3 PRODUCT PORTFOLIO

17.39.4 RECENT DEVELOPMENT

17.4 TEVA PHARMACEUTICALS

17.40.1 COMPANY SNAPSHOT

17.40.2 REVENUE

17.40.3 PRODUCT PORTFOLIO

17.40.4 RECENT DEVELOPMENT

17.41 UCB PHARMA

17.41.1 COMPANY SNAPSHOT

17.41.2 REVENUE

17.41.3 PRODUCT PORTFOLIO

17.41.4 RECENT DEVELOPMENT

17.42 WEST PHARMACEUTICAL SERVICES

17.42.1 COMPANY SNAPSHOT

17.42.2 REVENUE ANALYSIS

17.42.3 PRODUCT PORTFOLIO

17.42.4 RECENT DEVELOPMENTS

18 QUESTIONNAIRE

19 RELATED REPORTS

표 목록

TABLE 1 GLOBAL SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 2 GLOBAL SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 3 GLOBAL SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 4 GLOBAL SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 5 GLOBAL AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 6 GLOBAL PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 7 GLOBAL WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 8 GLOBAL NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 9 GLOBAL SELF-INJECTION FORMULATION IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 10 GLOBAL SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 11 GLOBAL SINGLE DOSE IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 12 GLOBAL MULTI-DOSE IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 13 GLOBAL SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 14 GLOBAL SUBCUTANEOUS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 15 GLOBAL INTRA MUSCULAR IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 16 GLOBAL OTHERS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 17 GLOBAL SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 18 GLOBAL AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 19 GLOBAL AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 20 GLOBAL PAIN MANAGEMENT IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 21 GLOBAL EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 22 GLOBAL EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 23 GLOBAL ONCOLOGY IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 24 GLOBAL HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 25 GLOBAL HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 26 GLOBAL OTHERS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 27 GLOBAL SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 28 GLOBAL ADULT IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 29 GLOBAL GERIATRIC IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 30 GLOBAL PEDIATRIC IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 31 GLOBAL SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 32 GLOBAL MALE IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 33 GLOBAL FEMALE IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 34 GLOBAL SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 35 GLOBAL DIRECT TENDER IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 36 GLOBAL HOSPITAL PHARMACY IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 37 GLOBAL ONLINE PHARMACY IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 38 GLOBAL OTHERS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 39 GLOBAL SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 40 NORTH AMERICA SELF-INJECTIONS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 41 NORTH AMERICA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 42 NORTH AMERICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 43 NORTH AMERICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 44 NORTH AMERICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 45 NORTH AMERICA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 46 NORTH AMERICA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 47 NORTH AMERICA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 48 NORTH AMERICA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 49 NORTH AMERICA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 50 NORTH AMERICA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 51 NORTH AMERICA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 52 NORTH AMERICA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 53 NORTH AMERICA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 54 NORTH AMERICA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 55 NORTH AMERICA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 56 NORTH AMERICA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 57 NORTH AMERICA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 58 U.S. SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 59 U.S. SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 60 U.S. SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 61 U.S. SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 62 U.S. AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 63 U.S. PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 64 U.S. WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 65 U.S. NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 66 U.S. SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 67 U.S. SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 68 U.S. SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 69 U.S. AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 70 U.S. EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 71 U.S. HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 72 U.S. SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 73 U.S. SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 74 U.S. SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 75 CANADA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 76 CANADA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 77 CANADA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 78 CANADA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 79 CANADA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 80 CANADA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 81 CANADA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 82 CANADA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 83 CANADA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 84 CANADA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 85 CANADA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 86 CANADA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 87 CANADA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 88 CANADA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 89 CANADA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 90 CANADA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 91 CANADA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 92 MEXICO SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 93 MEXICO SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 94 MEXICO SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 95 MEXICO SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 96 MEXICO AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 97 MEXICO PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 98 MEXICO WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 99 MEXICO NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 100 MEXICO SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 101 MEXICO SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 102 MEXICO SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 103 MEXICO AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 104 MEXICO EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 105 MEXICO HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 106 MEXICO SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 107 MEXICO SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 108 MEXICO SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 109 EUROPE SELF-INJECTIONS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 110 EUROPE SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 111 EUROPE SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 112 EUROPE SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 113 EUROPE SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 114 EUROPE AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 115 EUROPE PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 116 EUROPE WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 117 EUROPE NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 118 EUROPE SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 119 EUROPE SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 120 EUROPE SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 121 EUROPE AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 122 EUROPE EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 123 EUROPE HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 124 EUROPE SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 125 EUROPE SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 126 EUROPE SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 127 GERMANY SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 128 GERMANY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 129 GERMANY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 130 GERMANY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 131 GERMANY AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 132 GERMANY PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 133 GERMANY WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 134 GERMANY NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 135 GERMANY SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 136 GERMANY SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 137 GERMANY SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 138 GERMANY AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 139 GERMANY EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 140 GERMANY HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 141 GERMANY SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 142 GERMANY SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 143 GERMANY SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 144 U.K. SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 145 U.K. SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 146 U.K. SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 147 U.K. SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 148 U.K. AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 149 U.K. PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 150 U.K. WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 151 U.K. NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 152 U.K. SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 153 U.K. SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 154 U.K. SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 155 U.K. AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 156 U.K. EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 157 U.K. HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 158 U.K. SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 159 U.K. SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 160 U.K. SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 161 FRANCE SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 162 FRANCE SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 163 FRANCE SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 164 FRANCE SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 165 FRANCE AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 166 FRANCE PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 167 FRANCE WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 168 FRANCE NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 169 FRANCE SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 170 FRANCE SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 171 FRANCE SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 172 FRANCE AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 173 FRANCE EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 174 FRANCE HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 175 FRANCE SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 176 FRANCE SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 177 FRANCE SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 178 ITALY SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 179 ITALY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 180 ITALY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 181 ITALY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 182 ITALY AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 183 ITALY PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 184 ITALY WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 185 ITALY NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 186 ITALY SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 187 ITALY SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 188 ITALY SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 189 ITALY AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 190 ITALY EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 191 ITALY HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 192 ITALY SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 193 ITALY SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 194 ITALY SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 195 SPAIN SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 196 SPAIN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 197 SPAIN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 198 SPAIN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 199 SPAIN AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 200 SPAIN PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 201 SPAIN WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 202 SPAIN NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 203 SPAIN SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 204 SPAIN SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 205 SPAIN SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 206 SPAIN AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 207 SPAIN EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 208 SPAIN HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 209 SPAIN SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 210 SPAIN SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 211 SPAIN SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 212 RUSSIA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 213 RUSSIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 214 RUSSIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 215 RUSSIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 216 RUSSIA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 217 RUSSIA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 218 RUSSIA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 219 RUSSIA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 220 RUSSIA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 221 RUSSIA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 222 RUSSIA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 223 RUSSIA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 224 RUSSIA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 225 RUSSIA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 226 RUSSIA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 227 RUSSIA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 228 RUSSIA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 229 TURKEY SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 230 TURKEY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 231 TURKEY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 232 TURKEY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 233 TURKEY AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 234 TURKEY PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 235 TURKEY WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 236 TURKEY NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 237 TURKEY SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 238 TURKEY SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 239 TURKEY SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 240 TURKEY AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 241 TURKEY EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 242 TURKEY HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 243 TURKEY SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 244 TURKEY SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 245 TURKEY SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 246 BELGIUM SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 247 BELGIUM SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 248 BELGIUM SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 249 BELGIUM SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 250 BELGIUM AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 251 BELGIUM PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 252 BELGIUM WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 253 BELGIUM NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 254 BELGIUM SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 255 BELGIUM SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 256 BELGIUM SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 257 BELGIUM AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 258 BELGIUM EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 259 BELGIUM HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 260 BELGIUM SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 261 BELGIUM SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 262 BELGIUM SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 263 DENMARK SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 264 DENMARK SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 265 DENMARK SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 266 DENMARK SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 267 DENMARK AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 268 DENMARK PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 269 DENMARK WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 270 DENMARK NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 271 DENMARK SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 272 DENMARK SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 273 DENMARK SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 274 DENMARK AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 275 DENMARK EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 276 DENMARK HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 277 DENMARK SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 278 DENMARK SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 279 DENMARK SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 280 SWITZERLAND SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 281 SWITZERLAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 282 SWITZERLAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 283 SWITZERLAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 284 SWITZERLAND AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 285 SWITZERLAND PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 286 SWITZERLAND WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 287 SWITZERLAND NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 288 SWITZERLAND SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 289 SWITZERLAND SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 290 SWITZERLAND SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 291 SWITZERLAND AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 292 SWITZERLAND EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 293 SWITZERLAND HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 294 SWITZERLAND SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 295 SWITZERLAND SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 296 SWITZERLAND SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 297 NETHERLANDS SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 298 NETHERLANDS SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 299 NETHERLANDS SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 300 NETHERLANDS SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 301 NETHERLANDS AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 302 NETHERLANDS PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 303 NETHERLANDS WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 304 NETHERLANDS NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 305 NETHERLANDS SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 306 NETHERLANDS SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 307 NETHERLANDS SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 308 NETHERLANDS AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 309 NETHERLANDS EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 310 NETHERLANDS HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 311 NETHERLANDS SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 312 NETHERLANDS SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 313 NETHERLANDS SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 314 SWEDEN SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 315 SWEDEN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 316 SWEDEN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 317 SWEDEN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 318 SWEDEN AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 319 SWEDEN PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 320 SWEDEN WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 321 SWEDEN NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 322 SWEDEN SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 323 SWEDEN SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 324 SWEDEN SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 325 SWEDEN AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 326 SWEDEN EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 327 SWEDEN HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 328 SWEDEN SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 329 SWEDEN SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 330 SWEDEN SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 331 NORWAY SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 332 NORWAY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 333 NORWAY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 334 NORWAY SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 335 NORWAY AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 336 NORWAY PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 337 NORWAY WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 338 NORWAY NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 339 NORWAY SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 340 NORWAY SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 341 NORWAY SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 342 NORWAY AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 343 NORWAY EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 344 NORWAY HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 345 NORWAY SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 346 NORWAY SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 347 NORWAY SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 348 POLAND SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 349 POLAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 350 POLAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 351 POLAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 352 POLAND AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 353 POLAND PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 354 POLAND WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 355 POLAND NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 356 POLAND SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 357 POLAND SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 358 POLAND SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 359 POLAND AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 360 POLAND EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 361 POLAND HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 362 POLAND SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 363 POLAND SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 364 POLAND SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 365 FINLAND SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 366 FINLAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 367 FINLAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 368 FINLAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 369 FINLAND AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 370 FINLAND PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 371 FINLAND WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 372 FINLAND NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 373 FINLAND SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 374 FINLAND SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 375 FINLAND SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 376 FINLAND AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 377 FINLAND EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 378 FINLAND HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 379 FINLAND SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 380 FINLAND SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 381 FINLAND SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 382 REST OF EUROPE SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 383 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 384 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 385 ASIA-PACIFIC SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 386 ASIA-PACIFIC SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 387 ASIA-PACIFIC SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 388 ASIA-PACIFIC AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 389 ASIA-PACIFIC PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 390 ASIA-PACIFIC WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 391 ASIA-PACIFIC NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 392 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 393 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 394 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 395 ASIA-PACIFIC AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 396 ASIA-PACIFIC EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 397 ASIA-PACIFIC HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 398 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 399 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 400 ASIA-PACIFIC SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 401 CHINA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 402 CHINA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 403 CHINA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 404 CHINA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 405 CHINA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 406 CHINA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 407 CHINA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 408 CHINA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 409 CHINA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 410 CHINA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 411 CHINA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 412 CHINA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 413 CHINA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 414 CHINA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 415 CHINA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 416 CHINA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 417 CHINA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 418 INDIA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 419 INDIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 420 INDIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 421 INDIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 422 INDIA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 423 INDIA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 424 INDIA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 425 INDIA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 426 INDIA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 427 INDIA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 428 INDIA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 429 INDIA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 430 INDIA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 431 INDIA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 432 INDIA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 433 INDIA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 434 INDIA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 435 JAPAN SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 436 JAPAN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 437 JAPAN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 438 JAPAN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 439 JAPAN AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 440 JAPAN PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 441 JAPAN WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 442 JAPAN NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 443 JAPAN SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 444 JAPAN SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 445 JAPAN SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 446 JAPAN AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 447 JAPAN EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 448 JAPAN HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 449 JAPAN SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 450 JAPAN SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 451 JAPAN SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 452 SOUTH KOREA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 453 SOUTH KOREA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 454 SOUTH KOREA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 455 SOUTH KOREA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 456 SOUTH KOREA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 457 SOUTH KOREA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 458 SOUTH KOREA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 459 SOUTH KOREA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 460 SOUTH KOREA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 461 SOUTH KOREA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 462 SOUTH KOREA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 463 SOUTH KOREA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 464 SOUTH KOREA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 465 SOUTH KOREA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 466 SOUTH KOREA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 467 SOUTH KOREA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 468 SOUTH KOREA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 469 AUSTRALIA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 470 AUSTRALIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 471 AUSTRALIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 472 AUSTRALIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 473 AUSTRALIA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 474 AUSTRALIA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 475 AUSTRALIA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 476 AUSTRALIA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 477 AUSTRALIA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 478 AUSTRALIA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 479 AUSTRALIA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 480 AUSTRALIA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 481 AUSTRALIA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 482 AUSTRALIA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 483 AUSTRALIA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 484 AUSTRALIA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 485 AUSTRALIA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 486 THAILAND SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 487 THAILAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 488 THAILAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 489 THAILAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 490 THAILAND AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 491 THAILAND PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 492 THAILAND WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 493 THAILAND NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 494 THAILAND SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 495 THAILAND SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 496 THAILAND SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 497 THAILAND AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 498 THAILAND EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 499 THAILAND HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 500 THAILAND SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 501 THAILAND SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 502 THAILAND SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 503 MALAYSIA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 504 MALAYSIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 505 MALAYSIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 506 MALAYSIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 507 MALAYSIA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 508 MALAYSIA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 509 MALAYSIA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 510 MALAYSIA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 511 MALAYSIA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 512 MALAYSIA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 513 MALAYSIA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 514 MALAYSIA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 515 MALAYSIA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 516 MALAYSIA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 517 MALAYSIA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 518 MALAYSIA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 519 MALAYSIA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 520 SINGAPORE SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 521 SINGAPORE SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 522 SINGAPORE SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 523 SINGAPORE SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 524 SINGAPORE AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 525 SINGAPORE PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 526 SINGAPORE WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 527 SINGAPORE NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 528 SINGAPORE SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 529 SINGAPORE SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 530 SINGAPORE SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 531 SINGAPORE AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 532 SINGAPORE EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 533 SINGAPORE HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 534 SINGAPORE SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 535 SINGAPORE SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 536 SINGAPORE SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 537 INDONESIA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 538 INDONESIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 539 INDONESIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 540 INDONESIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 541 INDONESIA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 542 INDONESIA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 543 INDONESIA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 544 INDONESIA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 545 INDONESIA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 546 INDONESIA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 547 INDONESIA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 548 INDONESIA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 549 INDONESIA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 550 INDONESIA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 551 INDONESIA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 552 INDONESIA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 553 INDONESIA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 554 NEW ZEALAND SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 555 NEW ZEALAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 556 NEW ZEALAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 557 NEW ZEALAND SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 558 NEW ZEALAND AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 559 NEW ZEALAND PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 560 NEW ZEALAND WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 561 NEW ZEALAND NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 562 NEW ZEALAND SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 563 NEW ZEALAND SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 564 NEW ZEALAND SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 565 NEW ZEALAND AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 566 NEW ZEALAND EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 567 NEW ZEALAND HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 568 NEW ZEALAND SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 569 NEW ZEALAND SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 570 NEW ZEALAND SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 571 VIETNAM SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 572 VIETNAM SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 573 VIETNAM SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 574 VIETNAM SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 575 VIETNAM AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 576 VIETNAM PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 577 VIETNAM WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 578 VIETNAM NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 579 VIETNAM SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 580 VIETNAM SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 581 VIETNAM SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 582 VIETNAM AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 583 VIETNAM EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 584 VIETNAM HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 585 VIETNAM SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 586 VIETNAM SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 587 VIETNAM SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 588 TAIWAN SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 589 TAIWAN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 590 TAIWAN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 591 TAIWAN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 592 TAIWAN AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 593 TAIWAN PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 594 TAIWAN WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 595 TAIWAN NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 596 TAIWAN SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 597 TAIWAN SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 598 TAIWAN SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 599 TAIWAN AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 600 TAIWAN EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 601 TAIWAN HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 602 TAIWAN SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 603 TAIWAN SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 604 TAIWAN SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 605 PHILIPPINES SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 606 PHILIPPINES SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 607 PHILIPPINES SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 608 PHILIPPINES SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 609 PHILIPPINES AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 610 PHILIPPINES PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 611 PHILIPPINES WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 612 PHILIPPINES NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 613 PHILIPPINES SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 614 PHILIPPINES SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 615 PHILIPPINES SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 616 PHILIPPINES AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 617 PHILIPPINES EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 618 PHILIPPINES HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 619 PHILIPPINES SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 620 PHILIPPINES SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 621 PHILIPPINES SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 622 REST OF ASIA-PACIFIC SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 623 SOUTH AMERICA SELF-INJECTIONS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 624 SOUTH AMERICA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 625 SOUTH AMERICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 626 SOUTH AMERICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 627 SOUTH AMERICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 628 SOUTH AMERICA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 629 SOUTH AMERICA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 630 SOUTH AMERICA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 631 SOUTH AMERICA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 632 SOUTH AMERICA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 633 SOUTH AMERICA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 634 SOUTH AMERICA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 635 SOUTH AMERICA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 636 SOUTH AMERICA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 637 SOUTH AMERICA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 638 SOUTH AMERICA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 639 SOUTH AMERICA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 640 SOUTH AMERICA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 641 BRAZIL SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 642 BRAZIL SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 643 BRAZIL SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 644 BRAZIL SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 645 BRAZIL AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 646 BRAZIL PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 647 BRAZIL WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 648 BRAZIL NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 649 BRAZIL SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 650 BRAZIL SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 651 BRAZIL SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 652 BRAZIL AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 653 BRAZIL EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 654 BRAZIL HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 655 BRAZIL SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 656 BRAZIL SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 657 BRAZIL SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 658 ARGENTINA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 659 ARGENTINA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 660 ARGENTINA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 661 ARGENTINA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 662 ARGENTINA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 663 ARGENTINA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 664 ARGENTINA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 665 ARGENTINA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 666 ARGENTINA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 667 ARGENTINA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 668 ARGENTINA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 669 ARGENTINA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 670 ARGENTINA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 671 ARGENTINA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 672 ARGENTINA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 673 ARGENTINA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 674 ARGENTINA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 675 REST OF SOUTH AMERICA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 676 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 677 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 678 MIDDLE EAST AND AFRICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 679 MIDDLE EAST AND AFRICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 680 MIDDLE EAST AND AFRICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 681 MIDDLE EAST AND AFRICA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 682 MIDDLE EAST AND AFRICA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 683 MIDDLE EAST AND AFRICA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 684 MIDDLE EAST AND AFRICA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 685 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 686 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 687 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 688 MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 689 MIDDLE EAST AND AFRICA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 690 MIDDLE EAST AND AFRICA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 691 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 692 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 693 MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 694 SOUTH AFRICA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 695 SOUTH AFRICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 696 SOUTH AFRICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 697 SOUTH AFRICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 698 SOUTH AFRICA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 699 SOUTH AFRICA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 700 SOUTH AFRICA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 701 SOUTH AFRICA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 702 SOUTH AFRICA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 703 SOUTH AFRICA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 704 SOUTH AFRICA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 705 SOUTH AFRICA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 706 SOUTH AFRICA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 707 SOUTH AFRICA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 708 SOUTH AFRICA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 709 SOUTH AFRICA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 710 SOUTH AFRICA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 711 SAUDI ARABIA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 712 SAUDI ARABIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 713 SAUDI ARABIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 714 SAUDI ARABIA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 715 SAUDI ARABIA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 716 SAUDI ARABIA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 717 SAUDI ARABIA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 718 SAUDI ARABIA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 719 SAUDI ARABIA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 720 SAUDI ARABIA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 721 SAUDI ARABIA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 722 SAUDI ARABIA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 723 SAUDI ARABIA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 724 SAUDI ARABIA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 725 SAUDI ARABIA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 726 SAUDI ARABIA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 727 SAUDI ARABIA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 728 EGYPT SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 729 EGYPT SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 730 EGYPT SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 731 EGYPT SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 732 EGYPT AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 733 EGYPT PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 734 EGYPT WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 735 EGYPT NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 736 EGYPT SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 737 EGYPT SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 738 EGYPT SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 739 EGYPT AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 740 EGYPT EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 741 EGYPT HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 742 EGYPT SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 743 EGYPT SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 744 EGYPT SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 745 U.A.E SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 746 U.A.E SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 747 U.A.E SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 748 U.A.E SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 749 U.A.E AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 750 U.A.E PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 751 U.A.E WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 752 U.A.E NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 753 U.A.E SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 754 U.A.E SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 755 U.A.E SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 756 U.A.E AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 757 U.A.E EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 758 U.A.E HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 759 U.A.E SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 760 U.A.E SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 761 U.A.E SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 762 ISRAEL SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 763 ISRAEL SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 764 ISRAEL SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 765 ISRAEL SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 766 ISRAEL AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 767 ISRAEL PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 768 ISRAEL WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 769 ISRAEL NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 770 ISRAEL SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 771 ISRAEL SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 772 ISRAEL SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 773 ISRAEL AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 774 ISRAEL EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 775 ISRAEL HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 776 ISRAEL SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 777 ISRAEL SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 778 ISRAEL SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 779 KUWAIT SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 780 KUWAIT SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 781 KUWAIT SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 782 KUWAIT SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 783 KUWAIT AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 784 KUWAIT PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 785 KUWAIT WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 786 KUWAIT NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 787 KUWAIT SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 788 KUWAIT SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 789 KUWAIT SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 790 KUWAIT AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 791 KUWAIT EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 792 KUWAIT HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 793 KUWAIT SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 794 KUWAIT SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 795 KUWAIT SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 796 OMAN SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 797 OMAN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 798 OMAN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 799 OMAN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 800 OMAN AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 801 OMAN PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 802 OMAN WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 803 OMAN NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 804 OMAN SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 805 OMAN SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 806 OMAN SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 807 OMAN AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 808 OMAN EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 809 OMAN HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 810 OMAN SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 811 OMAN SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 812 OMAN SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 813 QATAR SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 814 QATAR SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 815 QATAR SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 816 QATAR SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 817 QATAR AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 818 QATAR PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 819 QATAR WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 820 QATAR NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 821 QATAR SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 822 QATAR SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 823 QATAR SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 824 QATAR AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 825 QATAR EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 826 QATAR HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 827 QATAR SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 828 QATAR SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 829 QATAR SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 830 BAHRAIN SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

TABLE 831 BAHRAIN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 832 BAHRAIN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 833 BAHRAIN SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)

TABLE 834 BAHRAIN AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 835 BAHRAIN PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 836 BAHRAIN WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 837 BAHRAIN NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 838 BAHRAIN SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)

TABLE 839 BAHRAIN SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 840 BAHRAIN SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 841 BAHRAIN AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 842 BAHRAIN EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 843 BAHRAIN HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 844 BAHRAIN SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)

TABLE 845 BAHRAIN SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 846 BAHRAIN SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 847 REST OF MIDDLE EAST AND AFRICA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)

그림 목록

FIGURE 1 GLOBAL SELF-INJECTIONS MARKET: SEGMENTATION

FIGURE 2 GLOBAL SELF-INJECTIONS MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL SELF-INJECTIONS MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL SELF-INJECTIONS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL SELF-INJECTIONS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL SELF-INJECTIONS MARKET: MULTIVARIATE MODELLING

FIGURE 7 GLOBAL SELF-INJECTIONS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 GLOBAL SELF-INJECTIONS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 GLOBAL SELF-INJECTIONS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL SELF-INJECTIONS MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 11 GLOBAL SELF-INJECTIONS MARKET: SEGMENTATION

FIGURE 12 TWO SEGMENTS COMPRISE THE GLOBAL SELF-INJECTIONS MARKET, BY PRODUCT TYPE

FIGURE 13 STRATEGIC DECISIONS

FIGURE 14 EXECUTIVE SUMMARY

FIGURE 15 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL SELF-INJECTIONS MARKET AND ASIA PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 16 SELF-INJECTION DEVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL SELF-INJECTIONS MARKET IN 2024 & 2031

FIGURE 17 ASIA PACIFIC IS THE FASTEST GROWING MARKET FOR THE GLOBAL SELF-INJECTIONS MARKET IN 2024 & 2031

FIGURE 18 DROC ANALYSIS

FIGURE 19 GLOBAL SELF-INJECTIONS MARKET: BY PRODUCT TYPE, 2023

FIGURE 20 GLOBAL SELF-INJECTIONS MARKET: BY PRODUCT TYPE, 2024-2031 (USD MILLION)

FIGURE 21 GLOBAL SELF-INJECTIONS MARKET: BY PRODUCT TYPE, CAGR (2024-2031)

FIGURE 22 GLOBAL SELF-INJECTIONS MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 23 GLOBAL SELF-INJECTIONS MARKET: BY DOSAGE FORM, 2023

FIGURE 24 GLOBAL SELF-INJECTIONS MARKET: BY DOSAGE FORM, 2024-2031 (USD MILLION)

FIGURE 25 GLOBAL SELF-INJECTIONS MARKET: BY DOSAGE FORM, CAGR (2024-2031)

FIGURE 26 GLOBAL SELF-INJECTIONS MARKET: BY DOSAGE FORM, LIFELINE CURVE

FIGURE 27 GLOBAL SELF-INJECTIONS MARKET: BY ROUTE OF ADMINISTRATION, 2023

FIGURE 28 GLOBAL SELF-INJECTIONS MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)

FIGURE 29 GLOBAL SELF-INJECTIONS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)

FIGURE 30 GLOBAL SELF-INJECTIONS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 31 GLOBAL SELF-INJECTIONS MARKET: BY APPLICATION, 2023

FIGURE 32 GLOBAL SELF-INJECTIONS MARKET: BY APPLICATION, 2024-2031 (USD MILLION)

FIGURE 33 GLOBAL SELF-INJECTIONS MARKET: BY APPLICATION, CAGR (2024-2031)

FIGURE 34 GLOBAL SELF-INJECTIONS MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 35 GLOBAL SELF-INJECTIONS MARKET: BY AGE GROUP, 2023

FIGURE 36 GLOBAL SELF-INJECTIONS MARKET: BY AGE GROUP, 2024-2031 (USD MILLION)

FIGURE 37 GLOBAL SELF-INJECTIONS MARKET: BY AGE GROUP, CAGR (2024-2031)

FIGURE 38 GLOBAL SELF-INJECTIONS MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 39 GLOBAL SELF-INJECTIONS MARKET: BY GENDER, 2023

FIGURE 40 GLOBAL SELF-INJECTIONS MARKET: BY GENDER, 2024-2031 (USD MILLION)

FIGURE 41 GLOBAL SELF-INJECTIONS MARKET: BY GENDER, CAGR (2024-2031)

FIGURE 42 GLOBAL SELF-INJECTIONS MARKET: BY GENDER, LIFELINE CURVE

FIGURE 43 GLOBAL SELF-INJECTIONS MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 44 GLOBAL SELF-INJECTIONS MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)

FIGURE 45 GLOBAL SELF-INJECTIONS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 46 GLOBAL SELF-INJECTIONS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 47 GLOBAL SELF-INJECTIONS MARKET: SNAPSHOT (2023)

FIGURE 48 GLOBAL SELF-INJECTIONS MARKET: COMPANY SHARE 2023 (%)

FIGURE 49 NORTH AMERICA SELF-INJECTIONS MARKET: COMPANY SHARE 2023 (%)

FIGURE 50 EUROPE SELF-INJECTIONS MARKET: COMPANY SHARE 2023 (%)

FIGURE 51 AISA-PACIFIC SELF-INJECTIONS MARKET: COMPANY SHARE 2023 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The market is segmented based on Global Self-Injections Market Segmentation, By Product Type (Self-Injection Devices and Self-Injection Formulation), Dosage Form (Single Dose and Multi-Dose), Route of Administration (Subcutaneous, Intra muscular and Others), Application (Autoimmune Diseases, Pain Management, Emergency Drugs, Oncology, Hormonal Disorders and Others), Age Group (Adult, Geriatric and Pediatric), Gender (Male and Female), Distribution Channel (Direct Tender, Hospital Pharmacy, Online Pharmacy and others) – Industry Trends and Forecast to 2031. .
The Global Self Injections Market size was valued at USD 46.18 USD Billion in 2023.
The Global Self Injections Market is projected to grow at a CAGR of 10% during the forecast period of 2024 to 2031.
The major players operating in the market include Bristol-Myers Squibb Company (U.S), Pfizer Inc. (U.S), Mylan N.V. (U.S), Merck & Co., Inc. (U.S), Bayer AG (Germany), GSK Group of Companies (U.K), AstraZeneca (U.K), Novartis AG (Switzerland), Baxter International Inc. (U.S), Antares Pharma (U.S), Penjet Corporation (U.S), Abbvie, Inc. (U.S), PharmaJet (U.S), Becton Dickinson & Company (U.S), Terumo Corporation (Japan).
The market report covers data from the U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy, Belgium, Russia, Switzerland, Netherlands, Turkey, Denmark, Sweden, Norway, Poland, Finland, Rest of Europe, China, Australia, Japan, India, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, New Zealand, Vietnam, Taiwan, Rest of Asia-Pacific, Brazil, Argentina, and rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, Kuwait, Oman, Qatar, Bahrain, and rest of Middle East and Africa.

관련 페이지 탐색

Banner